Multi-target therapies may address combined hypertension and dyslipidemia pathophysiology
Multi-Target Therapies May Address Combined Hypertension and High Cholesterol
This systematic review synthesizes evidence on synergistic mechanisms of hypertension and dyslipidemia, highlighting the RAAS/PPAR axis, AMP…
Combining treatments like statins and RAAS inhibitors may offer a more precise way to manage both high blood pressure and cholesterol levels…
Narrative review on PCSK9 inhibitors for familial hypercholesterolemia
Review explores PCSK9 inhibitors for familial hypercholesterolemia
This narrative review synthesizes evidence on PCSK9 inhibitors, including evolocumab, for familial hypercholesterolemia. The authors discuss…
This review looks at PCSK9 inhibitors like evolocumab for people with familial hypercholesterolemia. It discusses how these drugs work and t…
PCSK9 inhibitor initiation associated with lower depression risk versus statins in hyperlipidemia
Could lowering cholesterol with a new drug also protect against new episodes of depression?
A population-based cohort study of 35,610 adults with hyperlipidemia found PCSK9 inhibitor initiation was associated with lower risk of inci…
Starting a new cholesterol drug might lower the risk of developing depression compared to standard statins, based on data from over 35,000 a…